Defiance Nasdaq Junior Biotechnology ETF
IBBJ
IBBJ was delisted on the 2nd of December, 2021.
0 hedge funds and large institutions have $0 invested in Defiance Nasdaq Junior Biotechnology ETF in 2021 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 9 closing their positions.
100% less funds holding
Funds holding: 9 → 0 (-9)
100% less capital invested
Capital invested by funds: $887K → $0 (-$887K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 9
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IFG
Independent Financial Group
San Diego,
California
|
-$358K |
| 2 |
JIP
Jaffetilchin Investment Partners
Tampa,
Florida
|
-$252K |
| 3 |
TWM
Tradition Wealth Management
Edina,
Minnesota
|
-$149K |
| 4 |
ACA
Aptus Capital Advisors
Fairhope,
Alabama
|
-$44K |
| 5 |
IF
Ironwood Financial
Tucson,
Arizona
|
-$29K |
IBBJ Hedge Fund Activity: Q4 2021 in Review
0 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Defiance Nasdaq Junior Biotechnology ETF (IBBJ) for Q4 2021, worth a combined $0 — down 100% from $887K a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of IBBJ and 0 opened new positions — a net loss of 9 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Independent Financial Group, exiting entirely with an estimated $358K sold.
- 0 institutional investors held Defiance Nasdaq Junior Biotechnology ETF (IBBJ) as of Q4 2021, down from 9 in Q3 2021.
- Funds reported $0 of Defiance Nasdaq Junior Biotechnology ETF stock for Q4 2021, down 100% quarter-over-quarter.
- 0 funds opened new Defiance Nasdaq Junior Biotechnology ETF positions in Q4 2021 and 9 closed out, a net change of -9 holders.
- The largest Defiance Nasdaq Junior Biotechnology ETF seller in Q4 2021 was Independent Financial Group, an estimated $358K sold.
Based on aggregated 13F filings for Q4 2021.